Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2010

01-10-2010 | Thoracic Oncology

Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications

Authors: Ho Yun Lee, MD, Seung Hyup Hyun, MD, Kyung Soo Lee, MD, Byung-Tae Kim, MD, Jhingook Kim, MD, Young Mog Shim, MD, Myung-Ju Ahn, MD, Tae Sung Kim, MD, Chin A Yi, MD, Myung Jin Chung, MD

Published in: Annals of Surgical Oncology | Issue 10/2010

Login to get access

Abstract

Background

To evaluate the importance of assessing volume-based parameter of 18F-FDG PET/CT in patients with malignant pleural mesothelioma (MPM) for the prediction of response and patient outcome early in the course of treatment.

Materials and Methods

Patients (n = 13; M:F = 9:4, mean age, 54 years) with histopathologically proven MPM, all of whom were scheduled to undergo curative extrapleural pneumonectomy (EPP) or palliative chemotherapy, were included in this study. They were evaluated using integrated 18F-FDG PET/CT at baseline. Maximum standardized uptake value (SUVmax), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured using PET/CT data. Relationships between tumor progression and PET parameters were statistically analyzed.

Results

Of the 13 patients, 8 (62%) developed disease recurrence after surgery or tumor progression after chemotherapy (median follow-up, 329 days; range, 28–536 days). Between subgroups with and without tumor progression, significant differences were noted in MTV (P = 0.045). On ROC curve analysis, MTV (AUC = 0.850, 95% confidence interval [95% CI] 0.550–0.977) and TLG (AUC = 0.800, 95% CI 0.494–0.960) showed good predictive performance for tumor progression. Multivariate analysis adjusted for treatment modality showed that MTV (HR 1.003, P = 0.025) and TLG (HR 1.001, P = 0.031) were independent factors associated with tumor progression. Time to tumor progression was shorter in patients with a high volume-based parameter of PET than in those with a low value.

Conclusions

Volume-based parameters of 18F-FDG PET/CT have the potential to provide prognostic information in MPM patients who are receiving surgery or palliative chemotherapy.
Literature
1.
Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–7.CrossRefPubMed
2.
3.
Mirvis S, Dutcher JP, Haney PJ, Whitley NO, Aisner J. CT of malignant pleural mesothelioma. AJR Am J Roentgenol. 1983;140:665–70.PubMed
4.
Kawashima A, Libshitz HI. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol. 1990;155:965–9.PubMed
5.
Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–47.PubMed
6.
Armato SG, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006; 186:1000–6.CrossRefPubMed
7.
Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semi-automated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449–58.CrossRefPubMed
8.
Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new response evaluation criteria in solid tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer. 2004;43:71–4.CrossRefPubMed
9.
van Klaveren RJ, Aerts JGJV, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer. 2004;43:63–9.CrossRefPubMed
10.
Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60.CrossRefPubMed
11.
Armato SG, Oxnard GR, MacMahon H, Vogelzang NJ, Kindler HL, Kocherginsky M, et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004;31:1105–15.CrossRefPubMed
12.
Armato III SG, Oxnard GR, Kocherginsky M, Vogelzang NJ, Kindler HL, MacMahon H. Evaluation of semi-automated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005;12:1301–9.CrossRefPubMed
13.
Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest. 2004;125:2356–60.CrossRefPubMed
14.
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From The International Mesothelioma Interest Group. Chest. 1995;108:1122–8.CrossRefPubMed
15.
Yan TD, Boyer M, Tin MM, Bannon PG, McCaughan BC. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg. 2009;87:1552–6.CrossRefPubMed
16.
Shim SS, Lee KS, Kim B-T, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011–9.CrossRefPubMed
17.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–150S.CrossRefPubMed
18.
Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22.CrossRefPubMed
19.
Steinert HC, Dellea MMS, Burger C, Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET—CT imaging. Lung Cancer. 2005;49S1:S33–S35.CrossRef
20.
Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587–93.CrossRefPubMed
21.
Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010;67:311–7.CrossRefPubMed
22.
Jerusalem G, Belhocine TZ. Metabolic monitoring of chemosensitivity with 18FDG PET. Methods Mol Med. 2005;111:417–40.PubMed
23.
Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.PubMed
24.
Keyes JW, Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.PubMed
25.
Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34:392–404.CrossRefPubMed
Metadata
Title
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
Authors
Ho Yun Lee, MD
Seung Hyup Hyun, MD
Kyung Soo Lee, MD
Byung-Tae Kim, MD
Jhingook Kim, MD
Young Mog Shim, MD
Myung-Ju Ahn, MD
Tae Sung Kim, MD
Chin A Yi, MD
Myung Jin Chung, MD
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1107-z

Other articles of this Issue 10/2010

Annals of Surgical Oncology 10/2010 Go to the issue

Colorectal Cancer

Inadequate Quality of Surveillance after Curative Surgery for Colon Cancer

Colorectal Cancer

A New Concept for the Role of Ex vivo Sentinel Lymph Nodes in Node-Negative Colorectal Cancer

Bone and Soft Tissue Sarcomas

Radiographic and Histologic Response to Neoadjuvant Radiotherapy in Patients With Soft Tissue Sarcoma

Breast Oncology

Axillary Recurrence in Breast Cancer Patients with Isolated Tumor Cells in the Sentinel Lymph Node [AJCC N0(i+)]

Thoracic Oncology

Long-Term Survival and Prognostic Factors after Pulmonary Metastasectomy in Hepatocellular Carcinoma

Thoracic Oncology

CEA-Antigen and SCC-Antigen mRNA Expression in Peripheral Blood Predict Hematogenous Recurrence After Resection in Patients with Esophageal Cancer